BIO 2025, Huge Virtual Cell Dataset, AI-Designed De Novo Proteins

AcastBIO 2025, Huge Virtual Cell Dataset, AI-Designed De Novo ProteinsBIO 2025 is off and running. GEN editors discuss the size and scope of the bustling conference hall and share excitement about the week’s talks and panels. News from BIO includes the announcement of Lilly’s acquisition of Verve Therapeutics. Editors discuss the implications of industry-backed therapeutics amid cautious investors and public sentiment. In the realm of AI, Xaira Therapeutics, a $1 billion-backed AI drug discovery unicorn, has capped its first year by releasing the largest publicly available Perturb-seq dataset to support its virtual cell initiative. Additionally, AlphaDesign, a new AI-driven framework, accelerates the creation of functional de novo proteins, moving protein design toward custom therapeutics and precision medicine. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Uduak Thomas, and Fay Lin, PhD, for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching BaseLilly to Acquire Verve Therapeutics for Up to $1.3BBy Alex Philippidis, GEN Edge, June 17, 2025 Second DMD Patient Dies After Treatment with Sarepta Gene TherapyBy Alex Philippidis, GEN Edge, June 15, 2025Danon Disease Patient Dies in Rocket Gene Therapy TrialBy Alex Philippidis, GEN Edge, May 27, 2025Xaira Therapeutics Releases Largest Perturb-Seq Dataset to Power the Virtual CellBy Fay Lin, GEN Edge, June17, 2025AI-Designed Proteins Created De Novo with New AlphaDesignGEN, June 17, 2025 Hosted on Acast. See acast.com/privacy for more information.